Consistent with our hypothesis that the efficacy of BZM is determined by the E-selectin ligands on the tumor cells, we show that the remaining adhesions of BZM-sensitive cells on E-selectin-depleted ECs are not further reduced by BZM (although the EC treatment with BZM leads to reduced VCAM-1 expression). This evidence concerns the gene SELE and neoplasm.